Kevin Rooney

MedImmune LLC develops medicines for the prevention and treatment of infectious diseases such as cancer and immune system disorders. It offers solutions in the areas of monoclonal antibodies and vaccines for infection, oncology, respiratory disease and inflammation, cardiovascular diseases, and neuroscience. The company was founded by Wayne T. Hockmeyer in 1988 and is headquartered in Gaithersburg, MD.

GenVec, Inc. operated as a clinical-stage gene delivery company, which engaged in the development of therapeutics and vaccines. The firm designs, tests, and manufactured adenoviral-based product candidates using its proprietary AdenoVerse platform. Its products included CGF166-Hearing Loss; GV2311-RSV Vaccine; and GV2207-HSV-2 Immunotherapeutic. The company was founded in December 1992 and was headquartered in Rockville, MD.

National Foundation for Infectious Diseases engages in providing information and resources about vaccines recommended for adults, adolescents and children, including links to updated Center for Disease Control and Prevention (CDC) Immunization Schedules and a Fact Sheet about how vaccines work. The company is headquartered in Bethesda, MD.

Beacon Consulting Group, Inc. operates as a construction consulting firm. It offers surety consulting, construction management, pre-construction services and estimating, construction claims, funds control and construction loan monitoring, project control and scheduling services, construction defects assessment, and quality assurance and control. The company was founded by Robert Kaplan in 2000 and is headquartered in New York, NY.

QOL Medical LLC distributes bio pharmaceutical products. It offers treatment for gastroenterology, pharmaceuticals, biotechnology, orphan and rare diseases. The company was founded in 2003 and is headquartered in Vero Beach, FL.

F3 Platform Biologics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of novel and practical biotechnology for human use. It handles research, clinical development, and commercialization of new indications surrounding amifostine, a compound that has been previously approved by FDA for indications involving the prevention and treatment of side effects related to cancer treatment and radiation therapy. The company was founded on June 5, 2018 and is headquartered in Atlanta, GA.